Glycerol
Established medicineAlso known as Abreva Rapid Pain Relief, Aci-Jel, Blink Dry Eye, Cepacol Sore Throat Spray+26 more
Abreva Rapid Pain Relief, Aci-Jel, Blink Dry Eye, Cepacol Sore Throat Spray, Chloraseptic Max Spray, Colace Glycerin Suppositories, Glycerin Suppositories, Glycerin Topical, Glycerine, Glycerinum, Glyzerin, Monoctanoin component D, Oasis Tears, Osmoglyn, Pedia-Lax Liquid Glycerin Suppositories, Pretz, ProcalAmine 3, Propanetriol, Recticare Wipes, Regener-Eyes, Sani-Supp, Soothe Lubricant Eye Drops, Tears Naturale Forte, Trihydroxypropane, glycérine, Ölsüß, GLYCERIN, glycérol, 1,2,3-propanetriol, 1,2,3-trihydroxypropane.
Recent clinical, regulatory, research and industry developments relating to this drug.
Recall (Class II): GLYCERIN AND NAPHAZOLINE HYDROCHLORIDE AND ZINC SULFATE
Atmospheric kraft pulping in glycerol
Lactate and Glycerol Contribution to Gluconeogenesis
Effect of Lactoferrin Administration on Rhabdomyolysis-induced Heart and Kidney Injury in Rats
The Effects of Glycerol as an Optical Clearing Agent for Visualization of the Middle Ear
Visceral Adiposity and Diabetes: Translating Form to Function Using Imaging
Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Journals, researchers & institutions
- Journal of the American Society of Nephrology : JASN1
- Bruno S1
- Busca A1
- Bussolati B1
- Calogero RA1
- Camussi G1
- Collino F1
- Deregibus MC1
- Falda M1
- Research Center for Experimental Medicine1
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.